Clinical Trial Update: An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome [Phase 3]

View source ↗

Summary

An open-label extension study of BPN14770 for Fragile X Syndrome is ongoing in Phase 3 and is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• BPN14770

Snippet

Sponsor: Tetra Discovery Partners | Conditions: Fragile X Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING